ABCG2 and colorectal carcinoma: The whole study sets out to provide the probability of developing TOX3-WDR5/ABCG2 signaling axis as the candidate cascade therapeutic targets or biomarkers for adjuvant treatment or survival prediction in CRC patients receiving postoperative chemotherapy or with metastasis.